Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 [CNN]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: CNN
The $675 monthly list price is aimed at making the GLP-1 medications more accessible for patients whose costs are linked to the list price, including those who have high deductibles or who pay co-insurance for medications through their job-based plans. Wegovy's list price is currently $1,349 and Ozempic's and Rybelsus' list prices are $1,028, but those with insurance coverage can pay as little as $25 a month. The move is the latest in the GLP-1 price wars between Novo Nordisk and Eli Lilly, which manufactures the weight loss drug Zepbound and diabetes drug Mounjaro. Both companies are seeking to capture more of the soaring demand for obesity medications and have been lowering their prices for those willing to pay cash and forgo insurance. Both have also signed “Most Favored Nation” deals with the Trump administration, which included giving them expanded access to Medicare patients. The list price change does not have an impact on the self-pay prices, the Danish drugmaker said.
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026 [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: The New PayPal? [Seeking Alpha]Seeking Alpha
- Healthy Returns: What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss [CNBC]CNBC
- Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50% [FOX Business Network]FOX Business Network
- Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 [CNN]CNN
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/23/26 - Form 6-K
- 2/23/26 - Form 6-K
- 2/20/26 - Form 6-K
- NVO's page on the SEC website